PRAZOSIN HYDROCHLORIDE | N017442 | PFIZER LABORATORIES DIV PFIZER INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Appco Pharma LLC FDA-2026-P-5122 · 6 docket documents Appco Pharma LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting FDA approval to submit an ANDA for Prazosin Hydrochloride Capsules in 3 mg and 4 mg strengths, which differ from the Reference Listed Drug MINIPRESS (approved in 1 mg, 2 | Suitability | 2026-05-08 | Open | Appco Pharma LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1399
per ea
Lowest NADAC/Unit
$0.0823
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 66993043385PRAZOSIN 5 MG CAPSULE | $0.1399 | EA | Generic | — | 2026-06-17 |
| 66993043185PRAZOSIN 1 MG CAPSULE | $0.0853 | EA | Generic | — | 2026-06-17 |
| 66993043285PRAZOSIN 2 MG CAPSULE | $0.0823 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.